H.C. Wainwright on Travere Therapeutics (TVTX): 'We see adapted REMS as competitive advantage. We view this as positive news for Travere, particularly as it competes with Novartis’ (NVO; not rated)
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $47.00 price target on Travere Therapeutics (NASDAQ: TVTX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
